Rathbones Group PLC acquired a new position in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 983 shares of the medical instruments supplier's stock, valued at approximately $257,000.
Other large investors also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Insulet during the fourth quarter worth $248,806,000. Raymond James Financial Inc. purchased a new stake in shares of Insulet during the fourth quarter valued at $69,433,000. Alecta Tjanstepension Omsesidigt purchased a new position in Insulet during the 4th quarter worth approximately $53,184,000. Artisan Partners Limited Partnership boosted its stake in shares of Insulet by 24.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after buying an additional 149,524 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new stake in Insulet during the fourth quarter worth $28,422,000.
Insulet Stock Performance
Shares of NASDAQ PODD traded down $2.21 during midday trading on Tuesday, reaching $253.26. 108,825 shares of the company traded hands, compared to its average volume of 715,890. The stock has a 50-day moving average price of $266.08 and a 200 day moving average price of $260.72. The company has a market cap of $17.79 billion, a price-to-earnings ratio of 43.74, a PEG ratio of 3.62 and a beta of 1.30. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46.
Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Sell-side analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.
Analysts Set New Price Targets
PODD has been the topic of a number of recent research reports. Royal Bank of Canada started coverage on shares of Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price target on the stock. Canaccord Genuity Group increased their price objective on Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Citigroup boosted their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a report on Friday, February 21st. TD Cowen raised their target price on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Finally, Raymond James restated an "outperform" rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $292.06.
View Our Latest Research Report on PODD
Insider Transactions at Insulet
In related news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.
Insulet Profile
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Further Reading
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
